Marathon Digital Holdings Surges 21%

Prologis Raises FY22 Earnings Guidance

Prologis, Inc. (PLD) said the company now expects fiscal 2022 earnings per share in a range of $5.15 to $5.25. This represents an increase at midpoint of 5.6% from the previous guidance. Core FFO, excluding net promote income, is now expected in a range of $4.54 to $4.58, revised from prior guidance of $4.50 to $4.56.

Second-quarter net earnings attributable to common stockholders increased to $609.86 million from $598.63 million, last year. Net earnings per share was $0.82 compared to $0.81, prior year. Core funds from operations per share was $1.11 compared to $1.01.

Analysts on average had expected the company to earn $0.62 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

Total revenues increased to $1.25 billion from $1.15 billion, last year. Analysts on average had estimated $1.09 billion in revenue.

Shares of Prologis are up 2% in pre-market trade on Monday.

For more earnings news, earnings calendar, and earnings for stocks, visit

ProLogis Q2 Profit Increases, beats estimates

ProLogis (PLD) revealed earnings for its second quarter that increased from last year and beat the Street estimates.

The company’s earnings came in at $610 million, or $0.82 per share. This compares with $599 million, or $0.81 per share, in last year’s second quarter.

Excluding items, ProLogis reported adjusted earnings of $805 million or $1.11 per share for the period.

Analysts on average had expected the company to earn $0.62 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter rose 8.7% to $1.25 billion from $1.15 billion last year.

ProLogis earnings at a glance (GAAP) :

-Earnings (Q2): $610 Mln. vs. $599 Mln. last year.
-EPS (Q2): $0.82 vs. $0.81 last year.
-Analyst Estimate: $0.62
-Revenue (Q2): $1.25 Bln vs. $1.15 Bln last year.

Full year EPS guidance: $5.15 to $5.25

Apyx Medical Gets FDA 510(k) Clearance To Use Renuvion To Improve Appearance Of Loose Skin

Apyx Medical Corp. (APYX), a manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion, announced Monday that it has received 510(k) clearance from the U.S. Food and Drug Administration to use Renuvion APR Handpiece for certain skin contraction procedures.

The company said it expects to commence a limited launch of Renuvion for this indication by the end of the third quarter of 2022, with the goal of entering full commercialization by the end of 2022.

The Renuvion APR Handpieces are now indicated for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax or loose skin in the neck and submental region.

Charlie Goodwin, President and Chief Executive Officer, said, “We can now market and sell Renuvion to surgeons and patients for use in the approximately 200,000 neck contouring procedures performed in the U.S. Annually.”

Apyx Medical noted that Renuvion is now the only device that is FDA-cleared for improving the appearance of loose skin on the neck and chin.

The company’s 510(k) submission for this indication was supported by safety and efficacy data from a U.S. IDE clinical study focused on the use of Renuvion in these procedures.

For More Such Health News, visit

Casey Bloys Gets New Five-Year Contract At HBO, HBO Max

Casey Bloys, the hitmaker head of content at HBO and HBO Max is getting a new five-year contract from parent Warner Bros. Discovery.

The newly forged media conglom has been settling its executive slate and direction under CEO David Zaslav. The news comes a week after the premium network and streaming service secured 140 Emmy nominations.


Must Read Stories

Hollywood Unions Sign Off On Extension Of Covid Protocols Through September

‘Thor: Love & Thunder’ Crosses Half Billion; ‘Crawdads’ Croons $17M

Ricky Martin Denies “Sexual & Romantic Relationship” With Nephew, Lawyer Says; Hearing Set

‘Top Gun: Maverick’ Becomes Paramount’s Top-Grossing Pic Ever With $1.2B Global Haul

Read More About:

Dr Fauci plans to step down before the end of Joe Biden's first term

Dr Anthony Fauci, the US’s top infectious disease expert, has revealed he will step down from his post before the end of President Joe Biden’s first term.

‘I have said that for a long time,’ Fauci told CNN on Monday.

‘By the time we get to the end of Biden’s first term, I will very likely (retire).’

Biden’s current term ends in January 2025.

Breaking story, check back for updates…

Marathon Digital Holdings Surges 21%

Marathon Digital Holdings, Inc. (MARA) shares are surging more than 21 percent on Monday morning, continuing a rally, in tandem with the market trend today. There were no corporate announcements on the day to influence the stock movement.

Currently, shares are at $9.79, up 21.71 percent from the previous close of $8.04 on a volume of 10,365,677. The shares have traded in a range of $5.20-$83.45 on average volume of 12,978,473.